PRESS RELEASE

Krka Reports H1 2026 Business Results

Novo mesto
23 July 2026

In the first half of 2026, the Krka Group generated revenue of €1,119.3 million, up 7% year on year, yielding €260.2 million net profit, up 5%. The Supervisory Board of Krka discussed the Krka Group and Krka business report for the first half of 2026 at their regular meeting yesterday.

President of the Management Board and Chief Executive Officer Jože Colarič commented: 'As already reported at the Annual General Meeting (AGM) on 9 July, we performed very successfully in the first half of this year. We increased product and service sales in five sales regions and most of our markets, achieving record half-year sales. Our revenue totalled €1,119.3 million, a 7% increase year on year. Most of our operating results improved as well. EBITDA increased to €357.5 million, while EBITDA margin stood at 31.9%. EBIT reached €309.2 million, up 20%. Net profit increased as well, exceeding €260 million. We expanded our product portfolio with six prescription pharmaceuticals and one product for companion animals. We continued all key investment projects in Slovenia and abroad to increase the manufacturing capacity and strengthen our vertically integrated business model. We allocated €52.8 million to investments. At Krka, we remain committed to implementing our long-term dividend policy. Today, Krka shareholders are receiving a 2025 dividend of €9.10 gross per share, up just over 10% year on year, marking the 27th consecutive annual dividend increase. The AGM approved all proposed resolutions and authorised the Management Board to implement a new three-year share buyback programme. We will publish our nine-month results together with the 2026 business performance estimate and the 2027 business plan on 12 November 2026. Considering our performance in the first half of the year, we expect to meet our 2026 annual plan targets by the end of the year.'

Krka Group highlights

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Revenue	1,119,345	1,048,541	107
– Of which revenue from sales of products and services	1,113,781	1,045,775	107
Gross profit	682,260	607,385	112
Earnings before interest, tax, depreciation and amortisation (EBITDA)	357,453	303,254	118
Operating profit (EBIT)	309,225	256,977	120
Profit before tax (EBT)	319,950	299,414	107
Net profit	260,170	246,680	105
R&D expenses	100,052	94,857	105
Investments	52,829	40,886	129

Krka Group performance ratios

	Jan–Jun 2026	Jan–Jun 2025
Gross profit margin	61.0%	57.9%
EBITDA margin	31.9%	28.9%
EBIT margin	27.6%	24.5%
EBT margin	28.6%	28.6%
Net profit margin (ROS)	23.2%	23.5%
Return on equity (ROE)	20.8%	20.8%
Return on assets (ROA)	16.3%	16.5%
Liabilities/Equity	0.266	0.254
R&D expenses/Revenue	8.9%	9.0%

Krka Group sales

Product and service sales by region

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Region Slovenia	68,246	64,422	106
Region South-East Europe	159,406	148,196	108
Region East Europe	405,200	370,360	109
Region Central Europe	256,898	242,535	106
Region West Europe	181,863	187,021	97
Region Overseas Markets	42,168	33,241	127
Total	**1,113,781**	**1,045,775**	**107**

Product and service sales by region for H1 2026



The figures in parentheses show year-on-year changes in sales by region.

The Group's largest sales region was Region East Europe, recording product sales of €405.2 million. Product sales in the Russian Federation, our largest individual sales market, totalled €251.2 million, up 15% year on year. In Ukraine, product sales totalled €53.1 million, up 7% year on year. We also recorded sales growth in most other markets across eastern Europe and central Asia.

Region Central Europe followed with product sales of €256.9 million. Poland, our second largest individual sales market generated €128.2 million in product sales, a 5% year-on-year increase. Product sales amounted to €36.7 million (up 7%) in Czechia, and €31.0 million (up 11%) in Hungary. We also recorded sales growth in all other regional markets.

Generating €181.9 million, Region West Europe was the third largest sales region. In Germany, the largest regional sales market, product sales amounted to €47.1 million, on par with the same period last year. Our regional sales saw the highest increases in Ireland (up 6%) and Portugal (up 4%).

Region South-East Europe generated product sales of €159.4 million. We increased sales in all regional markets. In Romania, product sales totalled €40.6 million, up 1% year on year.

Product and service sales in Region Slovenia totalled €68.2 million. According to the latest available data for the first half of 2026, we retained the leading position among pharmaceutical suppliers, holding a 7.5% share of the Slovenian market.

Sales growth in Region Overseas Markets was primarily driven by higher sales in the Far East and African markets.

Product and service sales by group

€ thousand	Jan–Jun 2026	Jan–Jun 2025	Index
Human health products	1,020,375	956,176	107
– Prescription pharmaceuticals	943,943	878,260	107
– Non-prescription products	76,432	77,916	98
Animal health products	66,840	63,422	105
Health resort and tourist services	26,566	26,177	101
Total	**1,113,781**	**1,045,775**	**107**

Product and service sales by group for H1 2026



The figures in parentheses show year-on-year changes in sales by product and service group.

Research and development

In the first half of 2026, we expanded our product range with seven new products: six new prescription medicines and one animal health product. We market them under different brand names in individual markets. We finalised over 300 registration procedures for new and already established products in several markets.

We obtained first marketing authorisations for two single-pill antidiabetic combinations, Mempoglyn (empagliflozin/metformin) and Lymerexo (linagliptin/metformin). The two agents in film-coated tablets combine two active substances with synergistic modes of action, providing a modern and comprehensive approach to the treatment of type 2 diabetes, and allowing for patient-tailored therapies. We expanded our cardiovascular portfolio by obtaining marketing authorisations for Co-Pitavador (pitavastatin/ezetimibe), a single-pill combination indicated for the treatment of advanced hyperlipidaemia. Marketing authorisations were also granted for a new formulation of Dulsevia/Loxentia (duloxetine) hard gastro-resistant capsules. This established medicine is used in several therapeutic areas, but primarily to treat central nervous system disorders such as depression and anxiety, and to relieve pain caused by diabetic peripheral neuropathy in adults. We obtained marketing authorisations for two new products in China, bisoprolol/amlodipine combination tablets and edoxaban film-coated tablets. This further strengthened our presence in the treatment of chronic non-communicable diseases.

We expanded the range of animal health products for companion animals with marketing authorisations for our new product Robexera (robenacoxib) chewable tablets for cats, registered as Rogiola in certain countries. It is indicated for the control of pain and inflammation associated with musculoskeletal diseases and for the relief of moderate pain and inflammation after surgery.

Investments

In the first half of 2026, the Krka Group allocated €52.8 million to investments, of which €41.8 million to the controlling company.

The upgrades at the Notol plant in Novo mesto, Slovenia, are intended to ensure reliable operations over the next 20 years. We plan to upscale the production capacity by building an extension to the solid dosage production plant. We intend to increase the production capacities by installing additional equipment at Notol 2, another production plant in Novo mesto.

We completed the investment in additional capacities for tabletting mixture preparation, granulation, and logistics at the Solid Dosage Products plant in Novo mesto, Slovenia, and embarked on a new project to increase production output.

We installed a new suspension inspection line and finished building an extension for a new production line for sterile solutions at the Sterile Products Department in Novo mesto, Slovenia, to significantly enhance production volumes.

Work is in progress at the Bršljin Department in Novo mesto, Slovenia, to increase the production and packaging capacities for products for veterinary use. We also expect to boost the capacity for packaging tablets for use in veterinary medicine and spot-on solutions in the existing facility.

We increased the production capacity at the Ljutomer plant in Slovenia. Construction of an automated high-bay warehouse and an expansion of the plant are under way.

We completed construction of the technically and technologically advanced waste water treatment plant in Krško, Slovenia. Pre-treatment has been in operation since September 2025. We also put to use the remaining technological phases of the biological treatment, and the plant is currently in trial operation.

We are currently increasing production capacity at the production and distribution centre in Jastrebarsko, Croatia.

In China, we set up product manufacturing to support animal health programme. A filling-and-packaging line was installed and qualified.

Construction of research and production facilities for oncology products and solid dosage forms is underway at Krka Pharma Private Limited, a joint venture in Hyderabad, India.

Employees

At the end of June 2026, the Krka Group employed 13,300 persons, of whom 5,565 or 42% worked outside Slovenia. Of all Krka Group employees, 48% held at least a university degree, 206 held doctoral degrees.

Investor and share information

The Krka share price on the Ljubljana Stock Exchange increased by 23.4% over the first six months of 2026, and traded at €250.50 on 30 June 2026. The ownership structure remained stable, as there were no significant changes during this period. At the end of June 2026, Krka had 49,212 shareholders.

As at 30 June 2026, Krka's market capitalisation on the Ljubljana Stock Exchange, totalled €8.2 billion, including treasury shares. The average daily trading volume of Krka shares during this period amounted to €1.0 million.

In the first half of 2026, Krka acquired 81,754 treasury shares, and held 2,516,581 treasury shares as at 30 June 2026, equivalent to 7.674% of its share capital.

Sustainable operations

Sustainable operations and governance have long formed the foundation of the Krka Group's stable development and are fully integrated into our business processes. Our strategic sustainability priorities are aligned with the three strategic pillars of the 2026–2030 Krka Group Development Strategy. Our annual report, published on 9 April 2026, includes our second 'Sustainability statement', prepared in accordance with the European Sustainability Reporting Standards (ESRS). Compliance with the standards was attested by the external auditor. The 'Sustainability statement' provides key information on sustainability-related impacts, risks, and opportunities as well as the approach taken to manage them.

Krka received a score 55 out of 100 from S&P Global, confirming that the Krka Group pursues the right course in sustainable operations and governance.

Krka Group objectives for 2026

This year, the Krka Group projects revenue at €2,144 million and net profit at €405 million. We plan to allocate just over €140 million, primarily for expanding and modernising production facilities and infrastructure. Construction of production facilities at Krka Pharma Private Limited, our joint venture in India, is progressing as planned.

Press release on the 2026 performance estimates is due on 12 November 2026. Based on current estimates, we expect to meet our annual objectives by the end of the year.